Fight against childhood leukemia: Research in Duisburg shows groundbreaking approaches

Fight against childhood leukemia: Research in Duisburg shows groundbreaking approaches

Scientists at the University of Duisburg-Essen have developed a promising approach to treating aggressive childhood leukemias. With a funding commitment of 143,740 euros for a period of two years from the José Carreras Leukemia Foundation The team led by Prof. Dr. Shirley Knauer and Dr. Mike Blüggel at the Faculty of Biology describes the use of so-called nanobody PROTACs. This novel therapeutic approach aims to differentiate between two subtypes of leukemia and to specifically attack diseased tissue while sparing healthy cells.

The research team focuses on the enzyme Taspase 1, which plays a central role in the aggressive forms of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In an innovative step, the researchers are developing PROTACs that are specifically designed to break down Taspase 1. For the first time, this study exploits the internal degradation machinery of cancer cells to make this direct destruction effective.

Nanobody-PROTACs: A new approach to cancer research

By combining binding molecules and signals that stimulate cells to degrade activity, the scientists create a basis for precisely targeting the target protein Taspase 1. In addition, a novel approach is used in which helicons - spiral-like small proteins - are used to connect with degradation factors in order to enable the targeted destruction of the enzyme. Dr. Mike Blüggel highlights that this approach could potentially be groundbreaking for the personalized treatment of leukemia.

In the past, it has been challenging to develop effective strategies against Taspase 1, highlighting the relevance of these new research methods. By differentiating subtypes in the leukemia patient population, treatment could be made more targeted and less stressful in the future.

Research for the future

The developments at the University of Duisburg-Essen reflect significant progress in cancer research. Such innovative approaches are crucial, especially considering that childhood cancer often has long-term effects on quality of life. Research in this area is also supported by initiatives such as German Cancer Research Center (DKFZ) dedicated to personalized medical oncology. Remedial strategies enabled by precise molecular therapies could significantly improve treatment outcomes for affected children.

Overall, current research at the University of Duisburg-Essen shows how important and urgent innovative solutions are for combating childhood leukemia. Continued support of such projects could help increase survival rates and significantly improve the quality of life of young patients.